US, Russia reach deal on Syrian chemical weapons

September 14, 2013

Geneva, Sep 14: U.S. Secretary of State John Kerry and Russian Foreign Minister Sergey Lavrov reached agreement on Saturday on a framework for Syria to destroy all of its chemical weapons, and said they would seek a U.N. Security Council resolution that could authorize sanctions short of military action if President Bashar Assad's government fails to comply.Kerry-Lavrov

The deal announced by the diplomats on the third day of intense negotiations in Geneva includes what Kerry called “a shared assessment” of Syria's weapons stockpile, and a timetable and measures for Syria to comply.

The deal calls for international inspectors to be on the ground in Syria by November and to complete their initial work by the end of that that month. All of Syria's chemical weapons stocks, material and equipment would have to be destroyed or removed by mid-2014.

But the stakes have been especially high in Geneva, because the negotiations between the United States and Russia on securing Syria's chemical weapons also are considered key to breaking the international stalemate that has so far blocked a resumption of peace talks to end the Syrian civil war, now in its third year.

“We have committed to a standard that says, verify and verify,” Mr Kerry told a packed news conference in the Intercontinental Hotel in Geneva, where he has been staying and the negotiations were conducted since Thursday night.

Among the highlights of the agreement is that the U.S. and Russia would agree to work together on a new, binding Security Council resolution that would ensure verification of the agreement to secure and destroy Syria's chemical weapons stocks and remove its capability to produce such weapons.

The resolution would allow for punitive measures for non-compliance, but stop short of military action, if the 16-nation Security Council approves them. The U.S. and Russia are two of the five permanent Security Council members with a veto. The others are Britain, China, and France.

Another major feature of the agreement is that the U.S. and Russia plan to give Syria one week, until Sept. 21, to submit “a comprehensive listing, including names, types and quantities of its chemical weapons agents, types of munitions, and local and form of storage, production, and research and development facilities.”

In addition, the U.S. and Russia have agreed that international inspectors should be on the ground in Syria by November and complete their initial work by the end of the month. They must be given “immediate and unfettered” access to inspect all sites.

Notably, Mr Kerry said they had agreed on grounds under which they might request a Security Council “Chapter 7” resolution at the United Nations, which is a measure that could include military and non-military sanctions.

But Mr Lavrov, who said the agreement was “based on consensus and compromise and professionalism,” indicated there would be limits to using a Chapter 7 resolution, which Russia would almost certainly veto if it specifically authorized a military strike such as what President Barack Obama has threatened.

“Any violations of procedures ... would be looked at by the Security Council and if they are approved, the Security Council would take the required measures, concrete measures,” Mr Lavrov said.

“Nothing is said about the use of force or about any automatic sanctions. All violations should be approved by the Security Council,” he added.

Mr Kerry also said any violations will result in “measures” from the Security Council, while Mr Lavrov said the violations must be sent to the Security Council from the board of the chemical weapons convention before sanctions short of the use of force would be considered.

Mr Kerry said the pair and their teams of experts had come to agreement on the exact size of Syria's weapons stockpile, which had been a sticking point before their meetings in Geneva. But in marathon sessions into early morning hours, the U.S. and Russia succeeded in narrowing their differences.

The agreement over the Russian proposal to inventory, isolate and eventually destroy Syria's chemical weapons stocks comes as the Obama administration warned that there is a timetable for a diplomatic resolution of the weapons issue.

DPA adds

Meanwhile, the rebel Free Syrian Army (FSA) has rejected a U.S.-Russian deal on dismantling Syria's chemical weapons and has vowed to continue fighting to oust President Bashar al-Assad.

Comments

Add new comment

  • Coastaldigest.com reserves the right to delete or block any comments.
  • Coastaldigset.com is not responsible for its readers’ comments.
  • Comments that are abusive, incendiary or irrelevant are strictly prohibited.
  • Please use a genuine email ID and provide your name to avoid reject.
Agencies
July 29,2020

If everything goes as Russia’s expectation, it will be world’s first country to approve a coronavirus vaccine for widespread in the second week of August despite safety and efficacy concerns, according to a report. The adenoviral vector-based vaccine developed by Russian military and government researchers is currently in phase 2 trials.

According to a report from CNN, Russian officials are hoping to get approval for the COVID-19 vaccine developed by the Moscow-based Gamaleya Institute on Agust 10 or even before that. The officials told the outlet that the vaccine will be approved for public use with frontline healthcare workers receiving it first.

“It’s a Sputnik moment,” said Kirill Dmitriev, head of Russia’s sovereign wealth fund, which is financing Russian vaccine research, referring to the successful 1957 launch of the world’s first satellite by the Soviet Union, according to CNN.

“Americans were surprised when they heard Sputnik’s beeping. It’s the same with this vaccine. Russia will have got there first,” he was quoted as saying.

However, Russia is yet to release the scientific data on its coronavirus vaccine trials, hence, questions remain about the safety and efficacy of the vaccine, said the report. The vaccine is in the second phase of testing with developers planning to launch the phase 3 trials sometime after August 3.

Earlier, Interfax reported, citing Health Minister Mikhail Murashko, that the vaccine will be widely used in parallel with phase 3 trials. He said the country plans to vaccinate medics who are at high-risk for COVID-19 next month before clinical trials are completed.

Murashko added that individuals at higher risk of getting infected with the coronavirus such as older people or those with health conditions will also be prioritised for the vaccine, although he did not estimate or reveal when that would happen. The minister added 800 people will be recruited for the phase 3 trials.

Meanwhile, health officials were more cautious considering the fact that human testing of the vaccine is incomplete, and the state registration is expected to begin after August 3, reported The Moscow Times.

On Monday, Moderna and Pfizer announced the commencement of the final phase 3 trials of their candidate vaccines against the SARS-CoV-2 virus, which has so far claimed at least 654,477 lives and infected 16,514,500 people worldwide. 

Researchers will recruit up to 30,000 volunteers in separate trials both backed by the US government. India's first indigenous coronavirus vaccine, COVAXIN, is undergoing phase 1 human clinical trials across the country. More than 150 COVID-19 vaccines are being developed all over the world with at least six candidates already in late-stage clinical trials.

Comments

Add new comment

  • Coastaldigest.com reserves the right to delete or block any comments.
  • Coastaldigset.com is not responsible for its readers’ comments.
  • Comments that are abusive, incendiary or irrelevant are strictly prohibited.
  • Please use a genuine email ID and provide your name to avoid reject.
News Network
March 4,2020

Tokyo, Mar 4: Takeda Pharmaceutical Co said on Wednesday it was developing a drug to treat COVID-19, the flu-like illness that has struck more than 90,000 people worldwide and killed over 3,000.

The Japanese drugmaker is working on a plasma-derived therapy to treat high-risk individuals infected with the new coronavirus and will share its plans with members of the U.S. Congress on Wednesday, it said in a statement.

Takeda is also studying whether its currently marketed and pipeline products may be effective treatments for infected patients.

"We will do all that we can to address the novel coronavirus threat...(and) are hopeful that we can expand the treatment options," Rajeev Venkayya, president of Takeda's vaccine business, said in the statement.

Takeda said it was in talks with various health and regulatory agencies and healthcare partners in the United States, Asia and Europe to move forward its research into the drug.

Its research requires access to the blood of people who have recovered from the respiratory disease or who have been vaccinated, once a vaccine is developed, Takeda said.

Comments

Add new comment

  • Coastaldigest.com reserves the right to delete or block any comments.
  • Coastaldigset.com is not responsible for its readers’ comments.
  • Comments that are abusive, incendiary or irrelevant are strictly prohibited.
  • Please use a genuine email ID and provide your name to avoid reject.
Agencies
August 3,2020

New York, Aug 3: The number of coronavirus cases confirmed all over the world has surpassed 18 million, while the global COVID-19 death toll stands at over 687,000 according to data from the Johns Hopkins University's Coronavirus Resource Center.

As of 06:00 Moscow time on Monday (03:00 GMT), there are 18,017,556 confirmed coronavirus cases in the world. The global death toll from COVID-19 stands at 687,930. The number of recovered individuals stands at 10,649,108.

The United States remains the country with the largest number of cases (4,665,932) and the highest COVID-19 death toll (154,841), according to the latest data from the Johns Hopkins University.

Comments

Add new comment

  • Coastaldigest.com reserves the right to delete or block any comments.
  • Coastaldigset.com is not responsible for its readers’ comments.
  • Comments that are abusive, incendiary or irrelevant are strictly prohibited.
  • Please use a genuine email ID and provide your name to avoid reject.